Skip to main content
ARMP
NYSE Life Sciences

Armata 10-Q: $54.9M Q3 Net Income Is Non-Cash; Going Concern Flagged on $18.3M Cash

Arie Shkolnikov · Analysis by Wiseek AI
More coverage: Healthcare
Sentiment info
Negative
Importance info
8
Price
$3.72
Mkt Cap
$138.317M
52W Low
$2.745
52W High
$14.98
52W Position info
36% above low
Off High info
75% below high
Rel. Volume info
0.6× avg
Market data snapshot near publication time

ARMP sits 36% above its 52-week low of $2.745.

Summary

Armata's Q3 profit is entirely a non-cash convertible-loan remeasurement gain; the 10-Q flags substantial doubt about going concern with $18.3 million of cash that won't last 12 months, making a capital raise the central issue ahead of the planned AP-SA02 Phase 3 start.


Key Events · Earnings and Guidance · ARMP

  • Q3 Profit Is Non-Cash Loan Gain

    Net income of $54.9 million, or $1.15 per basic share, was driven by a $69.6 million gain from the change in fair value of the convertible loan — a non-cash mark-to-market entry, not an operating profit.

  • Going Concern on $18.3M Cash

    Cash and cash equivalents were $18.3 million at September 30, 2026, which the company states will not fund operations for the next 12 months, raising substantial doubt about its ability to continue as a going concern.

  • Operating Loss Widened

    Operating loss was $7.4 million for the quarter and $26.5 million for the nine months, versus $7.8 million and $22.8 million a year earlier.

  • DoW Funding Reaches $32.4M

    A September 18, 2026 modification added $3.7 million of non-dilutive DoW funding through MTEC, bringing the cumulative award to approximately $32.4 million.


Analysis · ARMP · Life Sciences

The $54.9 million quarterly net income is an accounting artifact: a $69.6 million non-cash gain from remeasuring the Innoviva convertible loan, driven by the share price, not operations. Operating loss was $7.4 million for the quarter and $26.5 million for the nine months. The real story is the going-concern warning: $18.3 million of cash will not fund operations for the next 12 months, so the company must raise capital — through equity (dilutive), more Innoviva debt, or partnerships — before the AP-SA02 Phase 3 trial, which is expected to start in the second half of 2026 but still hinges on FDA concurrence with the protocol. The $3.7 million September MTEC/DoW award increase to $32.4 million cumulative is non-dilutive but small against the burn.

How filings like this one have moved

In the 30 days to Nov 12, 2026, 47.3% of the 1873 measured filings Wiseek scored 8 moved their stock by 5% or more by the next session's close. The median move was -0.17%. These are measured outcomes after filings of this importance, not a forecast for this one.

Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset

At the time of this filing, ARMP was trading at $3.72 on NYSE in the Life Sciences sector, with a market capitalization of approximately $138.3M. The 52-week trading range was $2.75 to $14.98. This filing was assessed with negative market sentiment and an importance score of 8 out of 10.

View Main SEC Filing

Price Chart

Share this article

Copied!

ARMP - Latest Insights